Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/28/2019 |
| Start Date: | April 2016 |
| End Date: | November 25, 2018 |
The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect
depositions of a protein, called tau, in the brains of people with a mutation in the tau gene
that causes deposition of the protein, and in people without the mutation. Up to three
18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT
mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
depositions of a protein, called tau, in the brains of people with a mutation in the tau gene
that causes deposition of the protein, and in people without the mutation. Up to three
18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT
mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.
Inclusion Criteria:
- Members of families with established MAPT mutations, who either have the capacity to
consent to participate in the protocol, or else have designated a surrogate/proxy to
consent to participate in this study
Exclusion Criteria:
- Unwillingness to participate
- Usage of medication which significantly prolongs QT interval
- Pregnancy or plans for pregnancy within 90 days after participating in study
We found this trial at
1
site
Click here to add this to my saved trials
